Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Savient Pharmaceuticals Inc (SVNT)
since 2010 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Savient Pharmaceuticals Inc.
Table 2 shows the detailed insider transactions.
This company's CIK number is 722104.
Total stock buying since 2010: $276,607.
Total stock sales since 2010: $445,103.
Total stock option exercises since 2010: $88,597.
Table 3. Detailed insider trading at Savient Pharmaceuticals Inc (SVNT)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2013-12-04 | Thompson Virgil (Director) | Sale | 106,751 | .02 | 2,455 |
| 2013-10-17 | Jaeger Stephen O (Director) | Sale | 38,061 | .05 | 1,903 |
| 2013-10-16 | Bahrt Kenneth (SVP, Chief Medical Officer) | Sale | 8,000 | .07 | 584 |
| 2013-10-16 | Constantine Ginger (Director) | Sale | 8,805 | .07 | 642 |
| 2013-10-15 | Hamill John (Co-President and CFO) | Sale | 36,946 | .08 | 2,955 |
| 2013-10-15 | Bahrt Kenneth (SVP, Chief Medical Officer) | Sale | 70,211 | .08 | 5,757 |
| 2013-10-15 | Gionco David (Chief Accounting Officer) | Sale | 47,876 | .08 | 3,830 |
| 2013-10-15 | Crowley Richard (Co-President and COO) | Sale | 113,740 | .08 | 8,644 |
| 2013-10-15 | Yachmetz Philip K (Co-President and CBO) | Sale | 213,156 | .10 | 20,676 |
| 2013-05-22 | Ferrari Louis (President and CEO) | Sale | 1,020 | .57 | 581 |
| 2013-04-30 | Bahrt Kenneth (SVP, Chief Medical Officer) | Sale | 1,250 | .74 | 925 |
| 2013-04-30 | Crowley Richard (EVP, Chief Operating Officer) | Sale | 2,485 | .74 | 1,838 |
| 2013-03-06 | Gionco David (Group VP & Chief Acct. Officer) | Sale | 1,560 | .93 | 1,450 |
| 2013-02-25 | Ferrari Louis (President and CEO) | Sale | 375 | .99 | 371 |
| 2013-02-04 | Bahrt Kenneth (SVP, Chief Medical Officer) | Sale | 29,000 | 1.02 | 29,724 |
| 2013-02-04 | Ferrari Louis (President and CEO) | Sale | 62,200 | 1.01 | 63,132 |
| 2013-02-04 | Crowley Richard (EVP, Biopharmaceutical Ops) | Sale | 48,900 | 1.03 | 50,367 |
| 2013-02-04 | Yachmetz Philip K (SVP, General Counsel) | Sale | 30,500 | 1.01 | 30,957 |
| 2013-01-31 | Bahrt Kenneth (SVP, Chief Medical Officer) | Sale | 1,300 | 1.03 | 1,339 |
| 2013-01-31 | Crowley Richard (EVP, Biopharmaceutical Ops) | Sale | 2,415 | 1.02 | 2,463 |
| 2013-01-14 | Yachmetz Philip K (SVP, General Counsel) | Sale | 1,283 | 1.14 | 1,462 |
| 2012-11-26 | Ferrari Louis (President and CEO) | Sale | 950 | 1.16 | 1,102 |
| 2012-10-31 | Bahrt Kenneth (SVP, Chief Medical Officer) | Sale | 1,000 | 1.45 | 1,450 |
| 2012-10-31 | Crowley Richard (EVP, Biopharmaceutical Ops) | Sale | 2,010 | 1.45 | 2,914 |
| 2012-08-22 | Ferrari Louis (President and CEO) | Sale | 984 | 1.00 | 985 |
| 2012-08-02 | Crowley Richard (EVP, Biopharma Operatiotions) | Sale | 2,500 | .62 | 1,550 |
| 2012-08-01 | Bahrt Kenneth (SVP, Chief Medical Officer) | Sale | 4,950 | .62 | 3,069 |
| 2012-05-22 | Ferrari Louis (EVP, North American Commerical) | Sale | 942 | .82 | 772 |
| 2012-05-01 | Crowley Richard (EVP Biopharmaceutical Operatio) | Sale | 9,200 | 2.35 | 21,620 |
| 2012-02-22 | Ferrari Louis (EVP, North American Commerical) | Sale | 4,100 | 2.06 | 8,446 |
| 2012-02-14 | Yachmetz Philip K (SVP, General Counsel) | Sale | 3,540 | 2.02 | 7,150 |
| 2012-01-03 | Johnson John (Chief Executive Officer) | Sale | 17,650 | 2.30 | 40,595 |
| 2011-11-21 | Ferrari Louis (SVP, North American Commerical) | Buy | 4,000 | 2.29 | 9,160 |
| 2011-11-21 | Johnson John (CEO & President) | Buy | 5,000 | 2.30 | 11,500 |
| 2011-11-21 | Crowley Richard (EVP Biopharmaceutical Operatio) | Buy | 3,000 | 2.53 | 7,589 |
| 2011-11-18 | Johnson John (CEO & President) | Buy | 11,000 | 2.32 | 25,520 |
| 2011-11-18 | Zuerblis Kenneth J (EVP, Chief Financial Officer) | Buy | 2,000 | 2.35 | 4,690 |
| 2011-11-16 | Bahrt Kenneth (SVP, Chief Medical Officer) | Buy | 5,000 | 2.59 | 12,945 |
| 2011-09-16 | Johnson John (CEO & President) | Buy | 26,500 | 4.09 | 108,517 |
| 2011-09-16 | Yachmetz Philip K (SVP, General Counsel) | Buy | 7,000 | 4.13 | 28,910 |
| 2011-09-15 | Heller Alan L (Director) | Buy | 7,500 | 3.99 | 29,925 |
| 2011-09-15 | Zuerblis Kenneth J (EVP, Chief Financial Officer) | Buy | 4,000 | 4.05 | 16,187 |
| 2011-09-14 | Bahrt Kenneth (SVP, Chief Medical Officer) | Buy | 3,000 | 3.96 | 11,871 |
| 2011-09-14 | Johnson John (CEO & President) | Buy | 1,500 | 3.88 | 5,823 |
| 2011-09-14 | Zuerblis Kenneth J (EVP, Chief Financial Officer) | Buy | 1,000 | 3.97 | 3,970 |
| 2011-02-14 | Hamelin Paul (President) | Sale | 5,371 | 9.89 | 53,119 |
| 2011-02-14 | Yachmetz Philip K (SVP, General Counsel) | Sale | 3,210 | 9.88 | 31,724 |
| 2011-01-24 | Gionco David (Group VP & CFO) | Sale | 2,032 | 10.00 | 20,320 |
| 2010-12-20 | Gionco David (Group VP & CFO) | Sale | 1,536 | 11.87 | 18,232 |
| 2010-09-02 | Thompson Virgil (Director) | Option Ex | 7,500 | 11.81 | 88,597 |
Insider trading activities including stock purchases, stock sales, and option exercises
of SVNT listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Savient Pharmaceuticals Inc (symbol SVNT,
CIK number 722104) see
the Securities and Exchange Commission (SEC) website.